A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Purpose
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.
Condition
- Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Have liver fat content ≥8% - Have ELF score of ≥9 and ≤10.8 at screening - Have VCTE LSM ≥10 kilopascal (kPa) and <20 kPa at screening
Exclusion Criteria
- Have any other type of liver disease other than MASLD - Have a body mass index (BMI) <25 kilogram per square meter (kg/m2) - Prior decompensated liver disease (history of esophageal/gastric varices, ascites, hepatic encephalopathy) - Have lost more than 11 pounds within the 3 months prior to screening - Have a hemoglobin A1c (HbA1c) greater than 10% - Have type 1 diabetes
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Tirzepatide (TZ01) |
Participants will receive tirzepatide subcutaneously (SC) |
|
|
Placebo Comparator Placebo (TZ01) |
Participants will receive placebo SC |
|
|
Experimental Retatrutide (RT01) |
Participants will receive retatrutide SC |
|
|
Placebo Comparator Placebo (RT01) |
Participants will receive placebo SC |
|
Recruiting Locations
Chandler, Arizona 85224
Gilbert, Arizona 85297
Peoria, Arizona 85381
Sun City, Arizona 85351
Tucson, Arizona 85712
Tucson, Arizona 85715
520-257-3881
North Little Rock, Arkansas 72117
Canoga Park, California 91304
818-222-6868
Fountain Valley, California 92708
714-988-2021
Fresno, California 93720
559-970-3441
Lancaster, California 93534
661-388-2239
Long Beach, California 90815
562-997-1000
Los Angeles, California 90015
213-373-8380
Murrieta, California 92563
951-566-5229
Orange, California 92868
657-247-0087
Pasadena, California 91105
626-795-5769
Riverside, California 92503
951-374-1190
Englewood, Colorado 80113
Clermont, Florida 34711
407-426-9299
Daytona Beach, Florida 32114
Delray Beach, Florida 33484
401-773-7855
Fort Myers, Florida 33907
239-931-3368
Hollywood, Florida 33024
954-400-1725
Inverness, Florida 34452
352-341-2100
Jacksonville, Florida 32256
904-680-0871
Jupiter, Florida 33458
Lady Lake, Florida 32159
352-500-5252
Lakewood Rch, Florida 34211
941-727-7772
Largo, Florida 33777
727-724-3316
Miami, Florida 33122-1722
786-706-1216
Miami Lakes, Florida 33016-1518
305-330-9977
Naples, Florida 34102
239-571-0899
Orlando, Florida 32803
Orlando, Florida 32806
407-705-3471
Port Orange, Florida 32127
386-304-7070
Riverview, Florida 33578
941-894-2014
St. Petersburg, Florida 33710
877-791-0656
Tamarac, Florida 33321
877-791-0656
University Park, Florida 34201
941-894-2014
Dalton, Georgia 30720
706-913-1779
Marietta, Georgia 30060
404-786-3100
Indianapolis, Indiana 46202
317-278-1652
South Bend, Indiana 46635
574-904-9617
West Des Moines, Iowa 50266
515-329-6800
El Dorado, Kansas 67042
316-600-5127 EXT 301
Topeka, Kansas 66606
785-270-4800
Bastrop, Louisiana 71220
318-281-6040
Marrero, Louisiana 70072
504-934-8424
New Iberia, Louisiana 70560
813-851-0135
Shreveport, Louisiana 71105
318-525-3227
West Monroe, Louisiana 71291
New Bedford, Massachusetts 02740
Southfield, Michigan 48075
248-864-5242
Troy, Michigan 48098
248-312-0025
Flowood, Mississippi 39232
601-863-0395
Las Vegas, Nevada 89106
702-631-5000
Las Vegas, Nevada 89109
702-680-1500
Pennington, New Jersey 08534
215-676-6696
Warren Township, New Jersey 07059
New York, New York 10036
New York, New York 10075
Yonkers, New York 10701
Morehead City, North Carolina 28557
252-499-8623
Akron, Ohio 44320
Westlake, Ohio 44145
440-363-4000
Wyomissing, Pennsylvania 19610
610-374-4401
Providence, Rhode Island 02905
Chattanooga, Tennessee 37421
423-653-0842
Austin, Texas 78215
210-253-3426
Austin, Texas 78745
512-649-0082
Austin, Texas 78757
210-253-3426
Bellaire, Texas 77401
281-844-3160
Brownsville, Texas 78526
Denison, Texas 75020
469-819-0228
DeSoto, Texas 75115
197-277-7695
Edinburg, Texas 78539
956-309-3433
Farmers Branch, Texas 75234
214-347-7577
Forney, Texas 75126
972-564-0044
Houston, Texas 77004
Houston, Texas 77054
877-791-0656
Houston, Texas 77079
281-809-3234
Houston, Texas 77084
281-944-3610
Houston, Texas 77089
281-944-3610
McAllen, Texas 78503
281-944-3610
Mesquite, Texas 75149
214-693-0904
Pasadena, Texas 77505
832-847-1727
San Antonio, Texas 78229
210-949-0122
San Antonio, Texas 78229
210-692-7157
Shavano Park, Texas 78231
210-545-4900
Southlake, Texas 76092
940-367-2316
Sugar Land, Texas 77478
Weslaco, Texas 78596
956-431-8090
Wylie, Texas 75098
469-449-3645
Ogden, Utah 84403
801-614-0010
Sandy City, Utah 84070
801-409-2040
Bellevue, Washington 98004
425-454-4768
Charleston, West Virginia 25304
304-388-9944
Guaynabo, Puerto Rico 00968
7874045252
San Juan, Puerto Rico 00909
7879197865
More Details
- NCT ID
- NCT07165028
- Status
- Recruiting
- Sponsor
- Eli Lilly and Company
Study Contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
LillyTrials@Lilly.com